Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Oct 10;6(12):bvac152.
doi: 10.1210/jendso/bvac152. eCollection 2022 Oct 26.

Radiotherapy-Associated Pelvic Insufficiency Fracture Treated by Romosozumab: Course of CT Attenuations at L1 and L5

Gary K Schneider  1 , Steven W Ing  1
Affiliations
Case Reports

Radiotherapy-Associated Pelvic Insufficiency Fracture Treated by Romosozumab: Course of CT Attenuations at L1 and L5

Gary K Schneider et al. J Endocr Soc. .

Abstract

Pelvic radiation therapy (RT) is a risk factor for pelvic insufficiency fracture, which may be accompanied by significant pain, decreased self-sufficiency, and impaired mobility. Assessment of bone density with "opportunistic" computed tomography (CT) attenuation of the L1 vertebral body can be used as a surrogate for dual-energy x-ray absorptiometry (DXA) scan and potentially be useful to follow bone changes in cancer patients who undergo surveillance CT imaging. The following is a case of a 60-year-old female who suffered a pelvic insufficiency fracture, after receiving chemotherapy and pelvic RT for endometrial cancer, for which she was treated with romosozumab, a sclerostin inhibitor used for postmenopausal women at high risk for insufficiency or fragility fracture. CT attenuation of the L1 and L5 vertebral bodies were measured prior to chemoradiation therapy, post-therapy, and before and after treatment with romosozumab. Pelvic RT was associated with declining CT attenuation, greater in magnitude at L5 vs L1 vertebral body, while treatment with romosozumab was associated with increase to baseline at L1, and improvement but not return to baseline at L5.

Keywords: CT attenuation; endometrial carcinoma; pelvic insufficiency fracture; radiotherapy; romosozumab.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Bone turnover markers. Procollagen type 1 propeptide and C-telopeptide measurements at baseline prior to initiation of romosozumab and at months 4, 9, and 12 on treatment.
Figure 2.
Figure 2.
CT attenuation at L1 and L5. Lumbar CT attenuations were measured at L1 and L5 vertebral bodies at baseline prior to initiation of RT and after treatment with romosozumab.
Figure 3.
Figure 3.
Measuring lumbar CT attenuation. Lumbar CT Attenuation was measured as described by Pickhardt et al [27] by placing an oval region of interest over an area of vertebral body trabecular bone and measuring average Hounsfield Units.
See this image and copyright information in PMC

References

    1. Williams HJ, Davies AM. The effect of X-rays on bone: a pictorial review. Eur Radiol. 2006;16(3):619–633. - PubMed
    1. Willey JS, Lloyd SA, Nelson GA, Bateman TA. Ionizing radiation and bone loss: space exploration and clinical therapy applications. Clin Rev Bone Miner Metab. 2011;9(1):54–62. - PMC - PubMed
    1. Baxter NN, Habermann EB, Tepper JE, Durham SB, Virnig BA. Risk of pelvic fractures in older women following pelvic irradiation. JAMA. 2005;294(20):2587–2593. - PubMed
    1. Kwon JW, Huh SJ, Yoon YC, et al. Pelvic bone complications after radiation therapy of uterine cervical cancer: evaluation with MRI. Am J Roentgenol. 2008;191(4):987–994. - PubMed
    1. Ikushima H, Osaki K, Furutani S, et al. Pelvic bone complications following radiation therapy of gynecologic malignancies: clinical evaluation of radiation-induced pelvic insufficiency fractures. Gynecol Oncol. 2006;103(3):1100–1104. - PubMed

Publication types

LinkOut - more resources